Teva announces priority review granted by FDA for SD-809 for treatment of tardive dyskinesia
admin 16th March 2017 Uncategorised 0Teva Pharmaceutical Industries
More: Teva announces priority review granted by FDA for SD-809 for treatment of tardive dyskinesia
Source: MDlinx